ASTRO 2017: Perineural Invasion in Head and Neck Cancer

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video highlights an education session on the challenge of perineural invasion in head and neck cancer from the 2017 ASTRO Annual Meeting.

In this video, Richard Bakst, MD, of the Icahn School of Medicine at Mount Sinai in New York, reviews highlights of an education session on the challenge of perineural invasion in head and neck cancer from the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held last month in San Diego.

Recent Videos
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Less lymphocyte depletion with twice-daily radiotherapy warrants further assessment to optimize the synergistic effect of radiotherapy and immunotherapy.
Twice-daily thoracic radiotherapy appeared to confer less leukocyte and lymphocyte depletion compared with once-daily radiation in LS-SCLC.
The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Related Content
Researching the feasibility of consolidating extensive information into a unified cancer database is the “tip of the iceberg”, said Leila Tchelebi, MD.

Comprehensive Cancer Database May Enhance Personalized Therapy

Russ Conroy
October 15th 2025
Article

Researching the feasibility of consolidating extensive information into a unified cancer database is the “tip of the iceberg”, said Leila Tchelebi, MD.

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

Radiotherapy is a very evidence-based subject. We can tell quite accurately how well we think [a patient] is going to do.

How Has Radiotherapy Advanced in Cancer Treatment?

Tim Cortese
October 11th 2025
Article

Compared with 25 years ago, radiotherapy is much more personalized and targeted, thus reducing the strain on patients with cancer.

Imaging developments have made it possible to detect nodal recurrence at low PSA levels, which could help guide salvage approaches for prostate cancer.

Salvage Nodal Radiation Shows Tolerability, Low Toxicity in Prostate Cancer

Roman Fabbricatore
October 8th 2025
Article

Imaging developments have made it possible to detect nodal recurrence at low PSA levels, which could help guide salvage approaches for prostate cancer.

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Unraveling The Benefits of Twice-Daily Chemoradiotherapy in LS-SCLC

Russ Conroy
October 3rd 2025
Article

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Proton Vs Photon Therapy Yields Similar HRQOL in Non-Metastatic Breast Cancer

Proton Vs Photon Therapy Yields Similar HRQOL in Non-Metastatic Breast Cancer

Ariana Pelosci
September 30th 2025
Article

The RadComp Consortium trial showed comparable HRQOL between proton and photon therapy for patients with non-metastatic breast cancer.